Photo by nci from unsplash
In their recent paper, Santaliestra et al measured bone marrow (BM) Wilms' tumor (WT1) mRNA levels in patients with myeloid neoplasms treated with 5-azacytidine (5-AZA)1 . Patients with initial WT1 levels… Click to show full abstract
In their recent paper, Santaliestra et al measured bone marrow (BM) Wilms' tumor (WT1) mRNA levels in patients with myeloid neoplasms treated with 5-azacytidine (5-AZA)1 . Patients with initial WT1 levels greater than 100 copies but with a conversion to sustained levels below 100 had better overall survival (OS) compared to patients whose WT1 levels were always less than 100 copies. This article is protected by copyright. All rights reserved.
Keywords:
myeloid neoplasms;
tumor preferentially;
neoplasms treated;
treated azacytidine;
patients myeloid;
wilms tumor
Journal Title: European Journal of Haematology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!